A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

NCT02087176 ↗

Phase 2 Terminated 48 enrolled AstraZeneca

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell Lung Cancer Patients

Timeline

Start: 2014-03
Primary completion: 2015-05
Completion: 2015-05

Publications

Johnson ML, Dakhil SR, Beck JT, Sadiq A, Menon S, Mugundu GM, Chmielecki J, Spigel DR. Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer. Target Oncol. 2025 Nov;20(6):967-978. doi: 10.1007/s11523-025-01177-x. Epub 2025 Nov 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adavosertib	Small molecule	225 mg	Oral
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Pegfilgrastim	Protein / enzyme biologic	6 mg	Subcutaneous

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Summary

Timeline

Publications

Drugs

Indications